Cellyan Biotechnology Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Revenue	16.36	20.31	16.69	12.56
Revenue Growth (YoY)	-21.23%	21.72%	32.91%	-
Cost of Revenue	14.92	17.9	13.13	9.82
Gross Profit	1.44	2.42	3.56	2.74
Selling, General & Admin	2.06	2.22	1.89	1.76
Other Operating Expenses	0.04	0.07	0.06	-0.06
Total Operating Expenses	2.1	2.28	1.95	1.7
Operating Income	-0.66	0.13	1.61	1.04
Interest Income	0	0	0	0
Interest Expense	-0.11	-0.1	-0.08	-0.02
Total Non-Operating Income (Expense)	-0.11	-0.1	-0.08	-0.02
Pretax Income	-0.77	0.04	1.53	1.02
Provision for Income Taxes	-0.07	0.06	0.2	0.02
Net Income	-0.7	-0.03	1.33	1
Net Income to Common	-0.7	-0.03	1.33	1
Net Income Growth	-	-	33.21%	-
Shares Outstanding (Basic)	11	10	7	7
Shares Outstanding (Diluted)	11	10	7	7
Shares Change (YoY)	19.69%	38.56%	7.64%	-
EPS (Basic)	-0.07	-0.00	0.18	0.15
EPS (Diluted)	-0.07	-0.00	0.18	0.15
EPS Growth	-	-	23.29%	-
Free Cash Flow	-0.49	0.5	-0.45	1.61
Free Cash Flow Per Share	-0.05	0.05	-0.06	0.24
Gross Margin	8.80%	11.89%	21.32%	21.81%
Operating Margin	-4.04%	0.65%	9.64%	8.31%
Profit Margin	-4.29%	-0.13%	7.97%	7.95%
FCF Margin	-3.01%	2.46%	-2.68%	12.84%
EBITDA	0.43	1.21	2.53	1.76
EBITDA Margin	2.63%	5.93%	15.18%	14.00%
EBIT	-0.66	0.13	1.61	1.04
EBIT Margin	-4.04%	0.65%	9.64%	8.31%
Effective Tax Rate	8.96%	174.92%	12.86%	2.21%

SEC Filings: 10-K · 10-Q